
Lung Cancer Diagnostics Market Size, Share, and Outlook, 2025 Report- By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic
Description
Lung Cancer Diagnostics Market Outlook
Lung Cancer Diagnostics Market Size is forecast to register an optimistic growth rate of 9.2% from 2025 to 2032.. The Lung Cancer Diagnostics market is a thriving business that is poised to keep growing and presents potential growth opportunities for companies across the industry value chain.
The comprehensive market research report presents 12-year historic and forecast data on Lung Cancer Diagnostics segments across 22 countries from 2021 to 2032. Key segments in the report include By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales). Over 70 tables and charts showcase findings from our latest survey report on Lung Cancer Diagnostics markets.
Lung Cancer Diagnostics Market Insights, 2025
The lung cancer diagnostics market is experiencing significant growth due to the rising global burden of lung cancer, driven by increasing smoking rates, environmental pollution, and occupational exposure to carcinogens. Advances in imaging techniques, including low-dose computed tomography (LDCT), positron emission tomography (PET), and artificial intelligence (AI)-powered radiology, are improving early detection rates. Liquid biopsy and next-generation sequencing (NGS) are revolutionizing non-invasive diagnostics by enabling genetic profiling of tumors for personalized treatment. Additionally, government initiatives promoting lung cancer screening programs and the expanding role of biomarker-based blood tests are enhancing diagnostic efficiency. Pharmaceutical and biotech companies are increasingly investing in companion diagnostics to develop targeted therapies, further accelerating market growth.
Five Trends that will define global Lung Cancer Diagnostics market in 2025 and Beyond
A closer look at the multi-million global market for Lung Cancer Diagnostics identifies rapidly shifting consumer preferences across categories. By focusing on growth and resilience, leading Lung Cancer Diagnostics companies are prioritizing their investments across categories, markets, and geographies. The report analyses the most important market trends shaping the new landscape to support better decisions for the long and short-term future.
What are the biggest opportunities for growth in the Lung Cancer Diagnostics industry?
The Lung Cancer Diagnostics sector demonstrated remarkable resilience over the past year across developed and developing economies. Further, the market presents significant opportunities to leverage the existing momentum towards actions by 2030. On the other hand, recent macroeconomic developments including rising inflation and supply chain disruptions are putting pressure on companies. The chapter assists users to identify growth avenues and address business challenges to make informed commercial decisions with unique insights, data forecasts, and in-depth market analyses.
Lung Cancer Diagnostics Market Segment Insights
The Lung Cancer Diagnostics industry presents strong offers across categories. The analytical report offers forecasts of Lung Cancer Diagnostics industry performance across segments and countries. Key segments in the industry include- By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales). The largest types, applications, and sales channels, fastest growing segments, and the key factors driving each of the categories are included in the report.
Forecasts of each segment across five regions are provided from 2021 through 2032 for Asia Pacific, North America, Europe, South America, Middle East, and African regions. In addition, Lung Cancer Diagnostics market size outlook is provided for 22 countries across these regions.
Market Value Chain
The chapter identifies potential companies and their operations across the global Lung Cancer Diagnostics industry ecosystem. It assists decision-makers in evaluating global Lung Cancer Diagnostics market fundamentals, market dynamics, and disruptive trends across the value chain segments.
Scenario Analysis and Forecasts
Strategic decision-making in the Lung Cancer Diagnostics industry is multi-faceted with the increased need for planning across scenarios. The report provides forecasts across three case scenarios- low growth, reference case, and high growth cases.
Asia Pacific Lung Cancer Diagnostics Market Analysis- A Promising Growth Arena for Business Expansion
As companies increasingly expand across promising Asia Pacific markets with a combined population of over 4.5 billion, the medium-to-long-term future remains robust. The presence of the fastest-growing economies such as China, India, Thailand, Indonesia, and Vietnam coupled with strengthening middle-class populations and rising disposable incomes drive the market. In particular, China and India are witnessing rapid shifts in consumer purchasing behavior. China is recovering steadily with optimistic forecasts for 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
The State of Europe Lung Cancer Diagnostics Industry 2025- Focus on Accelerating Competitiveness
As companies opt for an integrated agenda for competitiveness, the year 2025 presents optimistic scenarios for companies across the ecosystem. With signs of economic recovery across markets, companies are increasing their investments. Europe is one of the largest markets for Lung Cancer Diagnostics with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. Increasing omnichannel shopping amidst robust consumer demand for value purchases shapes the market outlook. The report analyses the key Lung Cancer Diagnostics market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
The US Lung Cancer Diagnostics market Insights- Executives are most excited about opportunities for the US Lung Cancer Diagnostics industry.
Easing inflation coupled with strengthening consumer sentiment is encouraging aggressive actions from the US Lung Cancer Diagnostics companies. Market players consistently focusing on innovation and pursuing new ways to create value are set to excel in 2025. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Lung Cancer Diagnostics market.
Latin American Lung Cancer Diagnostics market outlook rebounds in line with economic growth.
Underlying demand remains higher among urban consumers with an optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries. Increased consumer spending has been reported since H2-2024 and the prospects remain strong for 2025. Aggressive ecosystem moves to create new sources of income are widely observed across markets in the region. Marketing activities focused on customer insights, operations, and support functions are quickly gaining business growth in the region.
Middle East and Africa Lung Cancer Diagnostics Markets- New Opportunities for Companies Harnessing Diversity
Rapid growth in burgeoning urban locations coupled with a young and fast-growing population base is attracting new investments in the Middle East and African Lung Cancer Diagnostics markets. Designing expansion and marketing strategies to cater to the local consumer base supports the market prospects. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies. On the other hand, Middle Eastern Lung Cancer Diagnostics markets including the UAE, Saudi Arabia, Qatar, and Oman continue to offer lucrative pockets of growth.
Competitive Landscape- How Lung Cancer Diagnostics companies outcompete in 2025?
The ability to respond quickly to evolving consumer preferences and adapt businesses to niche consumer segments remains a key growth factor. The report identifies the leading companies in the industry and provides their revenue for 2024. The market shares of each company are also included in the report. Further, business profiles, SWOT analysis, and financial analysis of each company are provided in detail. Key companies analyzed in the report include 20/20 Gene Systems, Abbott, Amoy Diagnostics Co. Ltd, Biocartis, Biodesix, Bio-Rad Laboratories Inc, Boditech Med Inc, Danaher, DiaSorin S.p.A., Exact Sciences UK Ltd, F. Hoffmann-La Roche Ltd., Guardant Health Inc, Inivata Ltd., LalPathLabs.com, LungLife AI Inc, MedGenome, Myriad Genetics Inc, Nanoentek, NanoString, NeoGenomics Laboratories, Oncocyte Corp, PerkinElmer Inc, PlexBio, QIAGEN, Quest Diagnostics Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc, Vela Diagnostics, Veracyte Inc.
Reasons to Buy the report
Lung Cancer Diagnostics Market Size is forecast to register an optimistic growth rate of 9.2% from 2025 to 2032.. The Lung Cancer Diagnostics market is a thriving business that is poised to keep growing and presents potential growth opportunities for companies across the industry value chain.
The comprehensive market research report presents 12-year historic and forecast data on Lung Cancer Diagnostics segments across 22 countries from 2021 to 2032. Key segments in the report include By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales). Over 70 tables and charts showcase findings from our latest survey report on Lung Cancer Diagnostics markets.
Lung Cancer Diagnostics Market Insights, 2025
The lung cancer diagnostics market is experiencing significant growth due to the rising global burden of lung cancer, driven by increasing smoking rates, environmental pollution, and occupational exposure to carcinogens. Advances in imaging techniques, including low-dose computed tomography (LDCT), positron emission tomography (PET), and artificial intelligence (AI)-powered radiology, are improving early detection rates. Liquid biopsy and next-generation sequencing (NGS) are revolutionizing non-invasive diagnostics by enabling genetic profiling of tumors for personalized treatment. Additionally, government initiatives promoting lung cancer screening programs and the expanding role of biomarker-based blood tests are enhancing diagnostic efficiency. Pharmaceutical and biotech companies are increasingly investing in companion diagnostics to develop targeted therapies, further accelerating market growth.
Five Trends that will define global Lung Cancer Diagnostics market in 2025 and Beyond
A closer look at the multi-million global market for Lung Cancer Diagnostics identifies rapidly shifting consumer preferences across categories. By focusing on growth and resilience, leading Lung Cancer Diagnostics companies are prioritizing their investments across categories, markets, and geographies. The report analyses the most important market trends shaping the new landscape to support better decisions for the long and short-term future.
What are the biggest opportunities for growth in the Lung Cancer Diagnostics industry?
The Lung Cancer Diagnostics sector demonstrated remarkable resilience over the past year across developed and developing economies. Further, the market presents significant opportunities to leverage the existing momentum towards actions by 2030. On the other hand, recent macroeconomic developments including rising inflation and supply chain disruptions are putting pressure on companies. The chapter assists users to identify growth avenues and address business challenges to make informed commercial decisions with unique insights, data forecasts, and in-depth market analyses.
Lung Cancer Diagnostics Market Segment Insights
The Lung Cancer Diagnostics industry presents strong offers across categories. The analytical report offers forecasts of Lung Cancer Diagnostics industry performance across segments and countries. Key segments in the industry include- By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales). The largest types, applications, and sales channels, fastest growing segments, and the key factors driving each of the categories are included in the report.
Forecasts of each segment across five regions are provided from 2021 through 2032 for Asia Pacific, North America, Europe, South America, Middle East, and African regions. In addition, Lung Cancer Diagnostics market size outlook is provided for 22 countries across these regions.
Market Value Chain
The chapter identifies potential companies and their operations across the global Lung Cancer Diagnostics industry ecosystem. It assists decision-makers in evaluating global Lung Cancer Diagnostics market fundamentals, market dynamics, and disruptive trends across the value chain segments.
Scenario Analysis and Forecasts
Strategic decision-making in the Lung Cancer Diagnostics industry is multi-faceted with the increased need for planning across scenarios. The report provides forecasts across three case scenarios- low growth, reference case, and high growth cases.
Asia Pacific Lung Cancer Diagnostics Market Analysis- A Promising Growth Arena for Business Expansion
As companies increasingly expand across promising Asia Pacific markets with a combined population of over 4.5 billion, the medium-to-long-term future remains robust. The presence of the fastest-growing economies such as China, India, Thailand, Indonesia, and Vietnam coupled with strengthening middle-class populations and rising disposable incomes drive the market. In particular, China and India are witnessing rapid shifts in consumer purchasing behavior. China is recovering steadily with optimistic forecasts for 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
The State of Europe Lung Cancer Diagnostics Industry 2025- Focus on Accelerating Competitiveness
As companies opt for an integrated agenda for competitiveness, the year 2025 presents optimistic scenarios for companies across the ecosystem. With signs of economic recovery across markets, companies are increasing their investments. Europe is one of the largest markets for Lung Cancer Diagnostics with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. Increasing omnichannel shopping amidst robust consumer demand for value purchases shapes the market outlook. The report analyses the key Lung Cancer Diagnostics market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
The US Lung Cancer Diagnostics market Insights- Executives are most excited about opportunities for the US Lung Cancer Diagnostics industry.
Easing inflation coupled with strengthening consumer sentiment is encouraging aggressive actions from the US Lung Cancer Diagnostics companies. Market players consistently focusing on innovation and pursuing new ways to create value are set to excel in 2025. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Lung Cancer Diagnostics market.
Latin American Lung Cancer Diagnostics market outlook rebounds in line with economic growth.
Underlying demand remains higher among urban consumers with an optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries. Increased consumer spending has been reported since H2-2024 and the prospects remain strong for 2025. Aggressive ecosystem moves to create new sources of income are widely observed across markets in the region. Marketing activities focused on customer insights, operations, and support functions are quickly gaining business growth in the region.
Middle East and Africa Lung Cancer Diagnostics Markets- New Opportunities for Companies Harnessing Diversity
Rapid growth in burgeoning urban locations coupled with a young and fast-growing population base is attracting new investments in the Middle East and African Lung Cancer Diagnostics markets. Designing expansion and marketing strategies to cater to the local consumer base supports the market prospects. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies. On the other hand, Middle Eastern Lung Cancer Diagnostics markets including the UAE, Saudi Arabia, Qatar, and Oman continue to offer lucrative pockets of growth.
Competitive Landscape- How Lung Cancer Diagnostics companies outcompete in 2025?
The ability to respond quickly to evolving consumer preferences and adapt businesses to niche consumer segments remains a key growth factor. The report identifies the leading companies in the industry and provides their revenue for 2024. The market shares of each company are also included in the report. Further, business profiles, SWOT analysis, and financial analysis of each company are provided in detail. Key companies analyzed in the report include 20/20 Gene Systems, Abbott, Amoy Diagnostics Co. Ltd, Biocartis, Biodesix, Bio-Rad Laboratories Inc, Boditech Med Inc, Danaher, DiaSorin S.p.A., Exact Sciences UK Ltd, F. Hoffmann-La Roche Ltd., Guardant Health Inc, Inivata Ltd., LalPathLabs.com, LungLife AI Inc, MedGenome, Myriad Genetics Inc, Nanoentek, NanoString, NeoGenomics Laboratories, Oncocyte Corp, PerkinElmer Inc, PlexBio, QIAGEN, Quest Diagnostics Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc, Vela Diagnostics, Veracyte Inc.
Reasons to Buy the report
- Make informed decisions through long and short-term forecasts across 22 countries and segments.
- Evaluate market fundamentals, dynamics, and disrupting trends set to shape 2025 and beyond.
- Gain a clear understanding of the competitive landscape, with product portfolio and growth strategies.
- Get an integrated understanding of the entire market ecosystem and companies.
- Stay ahead of the competition through plans for growth in a changing environment for your geographic expansion.
- Assess the impact of advanced technologies and identify growth opportunities based on actionable data and insights.
- Get free Excel spreadsheet and PPT versions along with the report PDF.
Table of Contents
196 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Lung Cancer Diagnostics Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Lung Cancer Diagnostics Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Lung Cancer Diagnostics Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Lung Cancer Diagnostics Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Lung Cancer Diagnostics Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Product
- Instruments
- Consumables & Accessories
- By Test
- Biomarkers Tests
- Imaging Test
- Biopsy
- Blood Test
- Others
- By End-User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
- By Distribution Channel
- Direct Tender
- Retail Sales
- 6. Global Lung Cancer Diagnostics Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Lung Cancer Diagnostics Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Lung Cancer Diagnostics Market Trends and Growth Opportunities
- 6.2.1 North America Lung Cancer Diagnostics Market Outlook by Type
- 6.2.2 North America Lung Cancer Diagnostics Market Outlook by Application
- 6.3 North America Lung Cancer Diagnostics Market Outlook by Country
- 6.3.1 The US Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 6.3.2 Canada Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 6.3.3 Mexico Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7. Europe Lung Cancer Diagnostics Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Lung Cancer Diagnostics Market Trends and Growth Opportunities
- 7.2.1 Europe Lung Cancer Diagnostics Market Outlook by Type
- 7.2.2 Europe Lung Cancer Diagnostics Market Outlook by Application
- 7.3 Europe Lung Cancer Diagnostics Market Outlook by Country
- 7.3.2 Germany Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7.3.3 France Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7.3.4 The UK Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7.3.5 Spain Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7.3.6 Italy Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7.3.7 Russia Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8. Asia Pacific Lung Cancer Diagnostics Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Lung Cancer Diagnostics Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Lung Cancer Diagnostics Market Outlook by Type
- 8.2.2 Asia Pacific Lung Cancer Diagnostics Market Outlook by Application
- 8.3 Asia Pacific Lung Cancer Diagnostics Market Outlook by Country
- 8.3.1 China Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8.3.2 India Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8.3.3 Japan Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8.3.4 South Korea Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8.3.5 Australia Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8.3.6 South East Asia Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 9. South America Lung Cancer Diagnostics Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Lung Cancer Diagnostics Market Trends and Growth Opportunities
- 9.2.1 South America Lung Cancer Diagnostics Market Outlook by Type
- 9.2.2 South America Lung Cancer Diagnostics Market Outlook by Application
- 9.3 South America Lung Cancer Diagnostics Market Outlook by Country
- 9.3.1 Brazil Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 9.3.2 Argentina Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 10. Middle East and Africa Lung Cancer Diagnostics Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Lung Cancer Diagnostics Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Lung Cancer Diagnostics Market Outlook by Type
- 10.2.2 Middle East and Africa Lung Cancer Diagnostics Market Outlook by Application
- 10.3 Middle East and Africa Lung Cancer Diagnostics Market Outlook by Country
- 10.3.1 Saudi Arabia Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 10.3.2 The UAE Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 10.3.4 South Africa Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 10.3.5 Egypt Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Lung Cancer Diagnostics Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- 20/20 Gene Systems
- Abbott
- Amoy Diagnostics Co. Ltd
- Biocartis
- Biodesix
- Bio-Rad Laboratories Inc
- Boditech Med Inc
- Danaher
- DiaSorin S.p.A.
- Exact Sciences UK Ltd
- F. Hoffmann-La Roche Ltd.
- Guardant Health Inc
- Inivata Ltd.
- LalPathLabs.com
- LungLife AI Inc
- MedGenome
- Myriad Genetics Inc
- Nanoentek
- NanoString
- NeoGenomics Laboratories
- Oncocyte Corp
- PerkinElmer Inc
- PlexBio
- QIAGEN
- Quest Diagnostics Inc
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc
- Vela Diagnostics
- Veracyte Inc
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.